The final analysis reported a 30% reduction in hospitalizations and deaths.As of January 2022, the Panoramic trial is testing molnupiravirs effectiveness. References
Further reading
Thorlund K, Sheldrick K, Meyerowitz-Katz G, Singh S, Hill A (March 2022). "Making Statistical Sense of the Molnupiravir MOVe-OUT Clinical Trial". Am J Trop Med Hyg. 106 (5): 1301–1304. doi:10.4269/ajtmh.21-1339. PMC 9128711. PMID 35276667. S2CID 247406958. External links

"Molnupiravir". Drug Information Portal. U.S. National Library of Medicine.
The prescribing information states that paroxetine should "not be used in combination with an MAOI (including linezolid, an antibiotic which is a reversible non-selective MAOI), or within 14 days of discontinuing treatment with an MAOI", and should not be used in combination with pimozide, thioridazine, tryptophan, or warfarin.Paroxetine interacts with the following cytochrome P450 enzymes:
CYP2D6 for which it is both a substrate and a potent inhibitor. CYP2B6 (strong) inhibitor. CYP3A4 (weak) inhibitor. CYP1A2 (weak) inhibitor. CYP2C9 (weak) inhibitor. CYP2C19 (weak) inhibitor.Paroxetine has been shown to be an inhibitor of G protein-coupled receptor kinase 2 (GRK2). Pharmacology
Pharmacodynamics
Paroxetine is the most potent and one of the most specific selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitors (SSRIs). It also binds to the allosteric site of the serotonin transporter, similarly, but less potently, than escitalopram. Paroxetine also inhibits the reuptake of norepinephrine to a lesser extent (<50 nmol/L). Based on evidence from four weeks of administration in rats, the equivalent of 20 mg paroxetine taken once daily occupies approximately 88% of serotonin transporters in the prefrontal cortex. Pharmacokinetics
Paroxetine is well-absorbed following oral administration. It has an absolute bioavailability of about 50%, with evidence of a saturable first pass effect. When taken orally, it achieves maximum concentration in about 6–10 hours and reaches steady-state in 7–14 days. Paroxetine exhibits significant interindividual variations in volume of distribution and clearance. Less than 2% of an oral dose is excreted in urine unchanged.Paroxetine is a mechanism-based inhibitor of CYP2D6.